Ankylosing spondylitis: secukinumab successful up to 3 years in MEASURE

  • Pavelka K & al.
  • ACR Open Rheumatol
  • 20 ene. 2020

  • de Miriam Davis, PhD
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • At doses of 150 and 300 mg, the IL-17 inhibitor secukinumab provides sustained improvements in signs and symptoms of active ankylosing spondylitis (AS) at 3-year follow-up.

Why this matters

  • Clinicians should feel confident that secukinumab is a good long-term treatment option for AS.

Study design

  • Prospective cohort (N=226) of patients who were initially randomly allocated to placebo or a loading dose of 10 mg/kg intravenous (IV) secukinumab followed by subcutaneous doses of 150 or 300 mg every 4 weeks.
  • At 16 weeks, the placebo group was randomly allocated to the 300- or 150-mg dose groups.
  • The primary outcome at week 156 was Assessment of Spondyloarthritis International Society (ASAS) improvement of at least 20% or 40% (ASAS 20/40).
  • Funding: Novartis.

Key results

  • Retention rates from weeks 16 to 156 were 80.5% with 300 mg and 80.9% with 150 mg.
  • ASAS 20/40 at week 156:
    • 68.2%/47.7% with 150 mg.
    • 75.0%/56.5% with 300 mg.
  • The 300-mg dose group had higher response rates than the 150-mg dose group on ASAS 40 and ASAS-PR (a score of 2 units or less in each of the 4 core ASAS domains [patient global, pain, function, and inflammation]).

Limitations

  • No imaging performed.